It provides the funding to developing countries to be able to purchase the medicines. That's probably the best way of describing it. Then it's up to the countries--with funding they get from the global fund and other donors like Canada, the United States, and the United Kingdom, and put in through their own budgets--to make decisions about how they can best access the most affordable and effective medicines they have put within their plans to provide to their populations.
CAMR is intended to provide them with another option through which they can access medicines. The intention of the WTO decision was for Canada and other WTO members to enable them to access medicines through compulsory licensing. If they decide that is the best means through which they can purchase the medicines to address the public health needs in their countries, that's the way they would undertake to do it.